Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 15/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | PLAT | P00750 | 2/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326283 | 0.88 | CYP11B1 (0.79) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1179546 | 0.86 | CYP11B1 (0.76) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15897010 | 0.82 | CYP11B1 (0.69) | CYP11B2CYP11B1CYP1A2CYP3A4CYP19A1 | |
| SCHEMBL3715051 | 0.82 | ATM (0.69) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1179594 | 0.81 | PLAU (0.73) | CYP11B2CYP11B1CYP1A2CYP3A4CYP19A1 | |
| SCHEMBL1179665 | 0.80 | CYP11B1 (0.66) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1179873 | 0.79 | PLAU (0.70) | CYP11B2CYP11B1CYP19A1HSD17B1HSD17B2 | |
| SCHEMBL3004402 | 0.79 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL641533 | 0.78 | CYP11B2 (0.64) | CYP11B2CYP11B1CYP1A2CYP3A4CYP19A1 | |
| SCHEMBL25002964 | 0.78 | CYP11B2 (0.63) | CYP11B2CYP11B1CYP1A2CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | CYP11B2 113/4885CYP11B1 70/4885CYP1A2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.